Great — here’s a compact, sourced market-reference pack for the Genome Editing market, with company references and the best publicly available revenue / value figures I could find (note: many genome-editing therapeutics companies have little product revenue and report mostly collaboration / licensing income; large instrument & reagent suppliers that support the field report full-company revenues). I’ve included the requested analysis sections and cited the most load-bearing sources.

This versatile research report is presenting crucial details on market relevant information, harping on ample minute details encompassing a multi-dimensional market that collectively maneuver growth in the global Genome Editing market.

This holistic report presented by the report is also determined to cater to all the market specific information and a take on business analysis and key growth steering best industry practices that optimize million-dollar opportunities amidst staggering competition in Genome Editing market.

Read complete report at: https://www.thebrainyinsights.com/report/genome-editing-market-12995

Quick market snapshot

  • Global market size (2024): ~USD 9.78 billion; projected to grow to roughly USD 25.0B by 2030 (CAGR ≈16.1% in many forecasts).

Key companies (who to watch) — company values / public figures (selected, latest public FY/annual numbers)

Note: many pure-play genome-editing biotech companies have small reported revenues (R&D / collaboration income). I list each firm with the best public revenue or reported figure and a short note on their genome-editing role.

  1. Thermo Fisher Scientific — Revenue (FY 2024): $42.88 billion. A leading supplier of instruments, reagents and services used across genome-editing workflows (CRISPR screening, sequencing, QC, bioprocessing).

  2. Merck KGaA / MilliporeSigma (Life Science) — Net sales (Merck Group, 2024): €21.2 billion. Supplies reagents, enzymes, and consumables used in gene-editing R&D and manufacturing.

  3. CRISPR Therapeutics (CRSP) — 2024 reported total revenue reported in company releases is very small (company reported extremely limited collaboration/license revenue in FY 2024 — press releases show minimal product revenue typical of early-stage biotech). (See CRISPR Therapeutics FY2024 update.)

  4. Editas Medicine (EDIT) — Revenue (2024): ~$32.3 million (largely collaboration/R&D revenue rather than product sales). Editas is a leading clinical-stage CRISPR company.

  5. Intellia Therapeutics (NTLA) — reported collaboration / overall revenue in 2024 at the tens of millions level (company filings show collaboration revenues and R&D-heavy P&L).

  6. Sangamo Therapeutics — Revenue (2024): $57.8 million (2023 was higher due to partnerships; Sangamo provides zinc-finger platforms and gene-editing technologies).

  7. Beam Therapeutics — 2024 license/collaboration revenue items reported in filings (overall small commercial revenue; company remains R&D-driven).

  8. Synthego (gene-editing tools & reagents) — private tools company; public estimates place 2024 revenue in the low-single-digit to low-double-digit millions (example third-party estimate: ~$9.1M), but verify with company statements for precision. Synthego supplies synthetic gRNAs, CRISPR kits, and engineering services.

Why these two tiers?

  • Tier A: large instruments / reagent / life-science suppliers (Thermo Fisher, Merck, Danaher, Agilent, Illumina) — large corporate revenues; they sell the platforms and consumables that enable genome-editing workflows.

  • Tier B: clinical genome-editing biotechs (CRISPR Therapeutics, Intellia, Editas, Beam, Sangamo) — typically R&D/collaboration-driven revenues today; value lies in pipelines and potential future therapeutics.

Recent developments (2023–2025)

  • Rapid progress of in-human trials for CRISPR and base-editing therapies (multiple companies advancing clinical programs), and increasing collaboration/licensing deals between big pharmas and genome-editing biotechs.

  • Large life-science suppliers continue to invest/acquire capabilities that speed design, QC, and manufacture of gene-edited products.

Drivers

  • Clinical progress and proof-of-concepts in gene-editing therapeutics (sickle cell disease, beta-thalassemia, rare genetic disorders).

  • Strong demand for research tools from academic labs, CROs and biotechs (CRISPR screens, high-throughput editing).

  • Advances in delivery (viral/non-viral) and base/prime editing expanding potential applications.

Restraints

  • Regulatory uncertainty for in-vivo editing and long-term safety questions (off-target edits, immune reactions).

  • High R&D and clinical development costs; many clinical programs remain pre-approval, limiting product revenues for therapeutics firms.

  • IP / freedom-to-operate complexities in CRISPR patent landscape.

Regional segmentation analysis

  • North America: largest commercial and clinical-trial hub (major biotechs, top academic centers, venture funding).

  • Europe: strong research base and growing clinical activity; cautious regulatory environment.

  • Asia-Pacific: fast-growing research and manufacturing base (China, South Korea, Japan) — strong adoption of genome-editing tools.

  • Rest of world: smaller but increasing adoption via multinational suppliers and CRO networks.

Emerging trends

  • Base editing & prime editing moving from lab demos to early clinical development.

  • Non-viral delivery systems (LNPs, nanoparticles) improving in-vivo feasibility.

  • Platform consolidation & vertical integration — large life-science companies bundling CRISPR design, synthesis, QC and bioprocessing capabilities.

Top use cases

  1. Therapeutic genome editing (in-vivo and ex-vivo therapies for genetic diseases).

  2. Research & target discovery (CRISPR screens, functional genomics).

  3. Agricultural / industrial strain engineering (crop traits, microbial strain improvement).

  4. Bioprocess cell-line engineering (CHO cell editing for biologics).

Major challenges

  • Long safety monitoring requirements and uncertain reimbursement for first-in-class gene-editing therapies.

  • Scaling GMP manufacture for cell and gene therapies (cost and capacity constraints).

  • Public perception & ethical/regulatory debate around germline vs somatic editing.

Attractive opportunities

  • Platform tools & services: sell-side (instruments, reagents, CDMO/CRO services) — steady revenue and lower regulatory risk than therapeutics. Thermo Fisher-class suppliers capture much of this.

  • Niche therapeutic approvals: first approvals (rare diseases) create high-value commercial opportunities.

  • Delivery tech & base/prime editing IP — companies that solve safe, efficient delivery and precise editing will command high value.

Key factors of market expansion

  • Clinical successes and regulatory approvals for editing therapeutics.

  • Wider adoption of automated, high-throughput editing & QC workflows in R&D and biomanufacturing.

  • Improvements in delivery methods and reduction of off-target effects.

Selected high-value sources (start here for verification / deeper data)

  • Grand View Research — Genome Editing Market (market size & forecast).

  • Thermo Fisher Scientific — 2024 Annual Report (FY 2024 revenue $42.88B).

  • Merck (Group) — 2024 net sales and Life-Science role.

  • Company filings / press releases for clinical genome-editing biotechs (CRISPR Therapeutics, Editas, Intellia, Sangamo, Beam) for their 2024 collaboration and revenue notes.

  • Synthego / private-company desk estimates for gene-editing reagent vendors.

If you’d like, I can now immediately produce one of these (pick one) and deliver it here:

  1. A vendor spreadsheet (CSV) with: company | HQ | FY-2024 revenue | role in genome editing (tools / reagents / therapeutics) | source links.

  2. A one-page PPTX: market size, top 10 vendors (with revenue bullets), and 3 go-to-market recommendations for a tools/CDMO vendor.

  3. A deep dive on a subsegment (e.g., base/prime editing therapeutics pipeline or gene-editing CDMO capacity & major providers), with company pipeline tables and citations.

Which would you like me to build next?